Pilot Source Coverage

This page tracks whether the first six GBA-PD source pages have been reflected in the wiki. “Mapped” means the section’s key contents are represented in a topic/entity page with a source link; it does not mean the canonical table has been copied verbatim.

Coverage Matrix

sourcesectionwiki targetstatus
20240722_181748Two Group Proportion ComparisonGBA-PD, Biomarkersmapped
20240722_181748GBA-PD / sPD / HC Biomarker MatrixBiomarkersmapped
20240722_181748Cognitive ReadoutsGBA-PDmapped
20240722_181748Summary / GD therapiesGBA Therapeuticsmapped
20240722_181748IsofagomineGBA Therapeuticslight map
20240722_181748EliglustatEliglustatmapped
20240722_181752Eliglustat continuationEliglustatmapped
20240722_181752Ambroxol mechanismAmbroxolmapped
20240722_181752Ambroxol preclinicalAmbroxolmapped
20240722_181752Ambroxol clinical trialsAmbroxolmapped
20240722_181756Ambroxol AMBITIOUS / ASPro-PD / AiM-PDAmbroxolmapped
20240722_181756Venglustat preclinicalVenglustatmapped
20240722_181756Venglustat in-house dataVenglustatmapped
20240722_181756Venglustat clinical trials P1Venglustatmapped
20240722_181800LEAPVenglustatmapped
20240722_181800MOVES-PDVenglustatmapped
20240722_181800PR001 in vitro / CBE preclinicalPR001mapped
20240722_181805PR001 CBE / 4L/PS-NA packagePR001mapped
20240722_181805PR001 biodistribution / lipid / alpha-syn figuresPR001mapped
20240722_181809PR001 4L/PS-NA and A53T + CBE figuresPR001mapped
20240722_181809PR001 NHP ICM biodistribution / GCasePR001mapped
20240722_181809PR001 dose selection and PROPEL rowPR001mapped; next photo needed

Pilot Gaps

gapnote
Full table duplicationDeliberately avoided; source tables remain canonical in by-photo files.
IsofagomineOnly one small P2 row appears in the pilot source; not enough for a full entity page yet.
PR001 clinical trialsThe first PROPEL row is clipped in 20240722_181809; expand from 20240722_181813.
Global uncertainty registerPilot uncertainties are carried on entity pages, but not yet rolled up globally.